Clinical Trial: Heparin Induced Thrombocytopenia: Pharmacoeconomics
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Study to Compare the Heparin Induced Thrombocytopenia Rates Associated With Heparin and Low Molecular Weight Heparin Usage as Well as Evaluate the Economic and Long-Term C
Brief Summary:
Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the purposes of this study.
Subsequently, we will compare the heparin induced thrombocytopenia rates associated with heparin and low molecular weight heparin usage as well as evaluate the economic and long-term clinical burden of heparin induced thrombocytopenia.
Detailed Summary:
The goal of this research is to investigate the outcomes and pharmacoeconomics of patients diagnosed with heparin induced thrombocytopenia (HIT).
Background:
Heparin induced thrombocytopenia (HIT) is a complication of heparin therapy receiving wide-scale awareness, increasing detection, and concern. Data from controlled studies demonstrate a lower incidence of HIT with low molecular-weight heparin (LMWH) when compared to unfractionated heparin (UFH) However, registry data comparing the incidence of HIT in patients receiving LWMH vs. UFH are scarce. We will define the incidence of HIT in patients receiving LWMH vs. UFH in the "real world" setting at Brigham and Women's Hospital. We will evaluate the associated clinical and economic implications.
Our Objectives are:
-
Compare the HIT rates associated with heparin and LMWH usage:
The incidence of HIT will be assessed for initial the type of heparin exposure responsible for causing HIT. Patients will be categorized as receiving UFH with or without LMWH or as receiving only LMWH.
-
Evaluate the economic burden of HIT to hospitals and/or payors:
We will capture all expenses associated with each patient admission. Hospital expenses will be tabulated daily using the hospital database and the proprietary cost accounting system, Transition Systems, Inc (TSI).
Expenses will be categorized by procedure or area of care and will include Emergency Department care, operating
Sponsor: Brigham and Women's Hospital
Current Primary Outcome: Clotting and Bleeding Complications [ Time Frame: 90 Days ]
Original Primary Outcome:
Current Secondary Outcome: Mortality [ Time Frame: 30 Days ]
Original Secondary Outcome:
Information By: Brigham and Women's Hospital
Dates:
Date Received: April 2, 2007
Date Started: July 2006
Date Completion:
Last Updated: February 26, 2009
Last Verified: February 2009
